top of page


Breast Cancer, HCP

Of about 300,000 new cases of breast cancer each year, about 20% of patients are HER2+.  Because of the success of targeted therapies, HCP’s view this status as promising and hopeful—but with significant limitations in later lines of therapy.  With new Product X, Healthcare practitioners can surpass these limitations, and expand boundaries for optimal care. 

*Concept 1 and 2 below presented as 2 of 3 creative concepts at winning pitch 

REVISED_canoe_final portfolio.jpg

Prostate Cancer, HCP

There is an extremely high unmet need in late line mCRPC, after a long fight HCPs and patient are left with few exciting options. BRCA1/2 genetic mutations are associated with a more aggressive disease and shorter survival. With the breakthrough therapy designation of Rubraca,  HCPs can offer a game-changing new line of therapy, creating new expectations for success. ​


Acute Myeloid Leukemia, HCP

In the treatment of one of the most deadly and common forms of Leukemia, it had been years since there had been a meaningful improvement in systemic treatment for patients unable to withstand intensive treatments. Venclexta delivers a potent, rapid response that can extend the quality and duration of survival among these patients, taking treatment outcomes beyond what was possible with current therapeutic approaches. 

Venclexta concepts_v8_Page_3.jpg
bottom of page